News
- Home
- Syncona’s Blue Earth gets good results in prostate cancer diagnosis
Syncona’s Blue Earth gets good results in prostate cancer diagnosis – Syncona has a large stake in Blue Earth Diagnostics. Blue Earth has been testing its prostate cancer diagnosis at a university hospital in Germany. The test (a radiohybrid PSMA-targeted agent, rhPSMA-7) for high-risk primary and recurrent prostate cancer was bought by Blue Earth in 2018. It wanted to extend its leading position in prostate cancer imaging (complementing its existing Axumin product), including potential new areas of high unmet need, such as early stage primary prostate cancer patients.
The Technical University at Munich has used the agent in early clinical experience in men with both primary and recurrent cancer. These retrospective analyses were presented at the Annual Urological Association’s 2019 Annual meeting:
Blue Earth expects to launch its own phase I/II clinical trial in 2019 calendar year.
Martin Murphy, Syncona Investment Management’s chief executive, said: “We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer. While Blue Earth will next look to test this hypothesis in its own clinical trial, this data reinforces our belief that this PSMA agent is one of the leading assets in the space and should enable Blue Earth to extend its leading position in prostate cancer diagnostics.”
Syncona has an 89.0 per cent stake in the business with a holding value of £229.6m.
SYNC : Syncona’s Blue Earth gets good results in prostate cancer diagnosis
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated